Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docaravimab + miromavimab
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Infiltration
01
Overview
Twinrab is a novel combination of two murine-derived monoclonal antibodies, docaravimab and miromavimab, developed by Zydus Lifesciences for rabies post-exposure prophylaxis. It is designed to provide immediate passive immunity by neutralizing the rabies virus at the site of infection, serving as a replacement for human or equine-derived rabies immunoglobulin (RIG). The two antibodies bind to distinct, non-overlapping epitopes on the rabies virus glycoprotein (G protein), ensuring broad-spectrum coverage against various rabies virus strains and reducing the risk of viral escape mutants. Twinrab is typically administered via infiltration into and around the wound, with any remaining volume injected intramuscularly at a site distant from the rabies vaccine injection.
- Brand names
- Twinrab
- Other names
- Docaravimab and Miromavimab
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on docaravimab + miromavimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docaravimab + miromavimab.